Studie - Chronic Pancreatitis Pain – Pipeline Review, H2 2012

Chronic Pancreatitis Pain — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Chronic Pancreatitis Pain - Pipeline Review, H2 2012', provides an overview of the Chronic Pancreatitis Pain therapeutic pipeline. This report provides information on the therapeutic development for Chronic Pancreatitis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pancreatitis Pain. 'Chronic Pancreatitis Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Chronic Pancreatitis Pain.
- A review of the Chronic Pancreatitis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Pancreatitis Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Pancreatitis Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Pancreatitis Pain pipeline depth and focus of Chronic Pancreatitis Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Chronic Pancreatitis Pain Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Chronic Pancreatitis Pain 7

Chronic Pancreatitis Pain Therapeutics under Development by Companies 9

Chronic Pancreatitis Pain Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Early Clinical Stage Products 13

Comparative Analysis 13

Chronic Pancreatitis Pain Therapeutics — Products under Development by Companies 14

Chronic Pancreatitis Pain Therapeutics — Products under Investigation by Universities/Institutes 15

Companies Involved in Chronic Pancreatitis Pain Therapeutics Development 16

Axcan Pharma Inc. 16

Chronic Pancreatitis Pain — Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Drug Profiles 22

Lyrica - Drug Profile 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Pioglitazone - Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

EUR-1066 - Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Namisol - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Chronic Pancreatitis Pain Therapeutics — Drug Profile Updates 26

Chronic Pancreatitis Pain Therapeutics — Discontinued Products 27

Chronic Pancreatitis Pain Therapeutics - Dormant Products 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 30

Disclaimer 30





List of Tables

Number of Products Under Development for Chronic Pancreatitis Pain, H2 2012 7

Products under Development for Chronic Pancreatitis Pain — Comparative Analysis, H2 2012 8

Number of Products under Development by Companies, H2 2012 9

Number of Products under Investigation by Universities/Institutes, H2 2012 10

Comparative Analysis by Late Stage Development, H2 2012 11

Comparative Analysis by Mid Clinical Stage Development, H2 2012 12

Comparative Analysis by Early Clinical Stage Development, H2 2012 13

Products under Development by Companies, H2 2012 14

Products under Investigation by Universities/Institutes, H2 2012 15

Axcan Pharma Inc., H2 2012 16

Assessment by Monotherapy Products, H2 2012 17

Assessment by Stage and Route of Administration, H2 2012 19

Assessment by Stage and Molecule Type, H2 2012 21

Chronic Pancreatitis Pain Therapeutics — Drug Profile Updates 26

Chronic Pancreatitis Pain Therapeutics — Discontinued Products 27

Chronic Pancreatitis Pain Therapeutics — Dormant Products 28





List of Figures

Number of Products under Development for Chronic Pancreatitis Pain, H2 2012 7

Products under Development for Chronic Pancreatitis Pain — Comparative Analysis, H2 2012 8

Products under Development by Companies, H2 2012 9

Products under Investigation by Universities/Institutes, H2 2012 10

Late Stage Products, H2 2012 11

Mid Clinical Stage Products, H2 2012 12

Early Clinical Stage Products, H2 2012 13

Assessment by Monotherapy Products, H2 2012 17

Assessment by Route of Administration, H2 2012 18

Assessment by Stage and Route of Administration, H2 2012 19

Assessment by Molecule Type, H2 2012 20

Assessment by Stage and Molecule Type, H2 2012 21

• Alcohol Addiction – Pipeline Review, H1 2013
• Anesthetic Effect – Pipeline Review, H1 2013
• Anorexia Nervosa Global Clinical Trials Review, H1, 2013
• Cancer Pain Global Clinical Trials Review, H1, 2013
• Chronic Pain – Pipeline Review, H1 2013
• Delirium Global Clinical Trials Review, H1, 2013
• Depression – Pipeline Review, H1 2013
• Dyskinesia Global Clinical Trials Review, H1, 2013
• Dyslexia Global Clinical Trials Review, H1, 2013
• Dystonia Global Clinical Trials Review, H1, 2013
• Friedreich Ataxia – Pipeline Review, H1 2013
• Global Neurostimulation Devices Market 2012-2016
• Inflammatory Pain Global Clinical Trials Review, H1, 2013
• Ischemic Stroke – Pipeline Review, H1 2013
• Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013
• Memory Impairment – Pipeline Review, H1 2013
• Mild Cognitive Impairment – Pipeline Review, H1 2013
• Partial Seizure – Pipeline Review, H1 2013
• Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2013
• Psychiatric Disorders – Pipeline Review, H1 2013